Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA

Vancomycin is the treatment of choice for infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Clinically, combinations of vancomycin (VAN) and beta-lactams have been shown to improve patient outcomes compared to VAN alone for the treatment of MRSA bloodstream infections. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhise, Ketki, Sau, Samaresh, Kebriaei, Razieh, Rice, Seth A., Stamper, Kyle C., Alsaab, Hashem O., Rybak, Michael J., Iyer, Arun K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073369/
https://www.ncbi.nlm.nih.gov/pubmed/30036944
http://dx.doi.org/10.3390/ma11071245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073369/
https://www.ncbi.nlm.nih.gov/pubmed/30036944
http://dx.doi.org/10.3390/ma11071245

Ejemplares similares